CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib.

MLA

Zhang, Lin, et al. “CRAFITY Score Benefits Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization and Lenvatinib.” Cancer Medicine, vol. 13, no. 12, June 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1002/cam4.7410.

APA

Zhang, L., Yang, H., Ning, S., Wu, Z., Wang, D., Liang, H., Wang, C., & Chang, X. (2024). CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib. Cancer Medicine, 13(12), 1–12. https://doi.org/10.1002/cam4.7410

Chicago

Zhang, Lin, Hongcai Yang, Shangkun Ning, Zhijuan Wu, Dianzhe Wang, Hexin Liang, Chunni Wang, and Xu Chang. 2024. “CRAFITY Score Benefits Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization and Lenvatinib.” Cancer Medicine 13 (12): 1–12. doi:10.1002/cam4.7410.